Skopos Labs, Inc. Cullinan Oncology, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 4,503 shares of CGEM stock, worth $34,042. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,503
Previous 4,503
-0.0%
Holding current value
$34,042
Previous $34,000
2.94%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
152Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$57.8 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$43.5 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$33.3 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$29.1 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$26.8 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $345M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...